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Structured Abstract 
Purpose:    
To review the definition of ischaemic central retinal vein occlusion (CRVO) and 
stratify the risk of neovascular complication based on wider areas of visible retinal 
non-perfusion. 
Design:  
Retrospective consecutive case series and image analysis study 
Methods:    
Setting: Moorfields Eye Hospital, London, United Kingdom. 
Study Population: 42 consecutive treatment naïve eyes with CRVO imaged with 
ultra-widefield angiography with a minimum of 12 months follow-up. 
Observation Procedure: The spatial location and total area of retinal non-perfusion 
(measured in disc areas, DA) were determined using the validated concentric rings 
method. The area was corrected for projection distortion. The images were graded 
by two retinal physicians and average measurements used.  
Main Outcome Measures: Development of neovascular complications. 
Results:    
The percentage of eyes developing new vessels increased from none in eyes with 
less than 10 DA of non-perfusion in total, to 14.3% in eyes with 10-30DA, 20.0% for 
30-75DA and 80% risk with 75-150DA of non-perfusion. From 13 (31.0%) eyes with 
a perfused posterior pole (an area encompassing a five disc diameter radius 
centered at the fovea) and more than 10DA of non-perfusion isolated in the 
periphery (beyond the posterior pole), only one (7.7%) eye developed new vessels, 
OR 0.12 [95% CI:0.01,1.03]. Comparatively, for 13 (31.0%) eyes with more than 
10DA of non-perfusion in the posterior pole, 11 (84.6%) developed new vessels, OR 
74.25 [95% CI: 9.26, 595.30], p<0.001. 
Conclusion: 
With ultra-widefield angiography, we have ascertained that posterior pole non-
perfusion of more than 10DA remains the key risk factor for new vessel development 
compared to areas of non-perfusion confined to the periphery.  
(250 words) 
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Main Text 
 
Introduction 
Our understanding of the natural history of central retinal vein occlusion CRVO is 
based on the observations reported in the Central Vein Occlusion Study (CVOS). 
The study showed that 35% of non-perfused eyes and 10% of perfused eyes at 
baseline progressed to anterior segment neovascularization over a three year period 
with the majority within the first year.1 In the control arm of the CVOS, among eyes 
with more than 10 disc areas of retinal capillary non-perfusion, the risk of developing 
anterior segment neovascularization was 35% with no prophylactic treatment and 
this risk reduced to 20% when prophylactic panretinal photocoagulation was 
administered.2 Based on these findings, ischemic CRVO is defined as an eye with 10 
disc areas or more of non-perfusion and the risk of anterior segment 
neovascularization increased significantly in eyes with more than 30 disc areas of 
non-perfusion. 2 The Standard Care vs. Corticosteroid for Retinal Vein Occlusion 
(SCORE) study report number 11, on the other hand, suggested the limits of 5.5 disc 
areas as an indicator of ischemia with an incidence of anterior segment 
neovascularization of 23.6% and only 5.9% with less than 5.5 disc areas of non-
perfusion.3 The imaging methods used in these landmark studies were limited to the 
standard 30-degree seven field ETDRS protocol in SCORE and five field views using 
60-degree images or eight standard views using 30-degree images in CVOS.2,4 
Therefore, the areas of perfusion visualized were limited.   
Ultra-widefield imaging has allowed visualization of up to three times the area 
captured with a standard 7-field imaging protocol in a single capture.5 So the area of 
retinal capillary non-perfusion observed using ultra-widefield angiography is also 
significantly greater.6 Therefore, a question has risen as to whether the definition of 
ischemic CRVO needs to be revised in light of the greater area of non-perfusion 
noted on ultra-widefield angiography. Using a standard 10 disc areas of non-
perfusion interchangeably with different imaging modalities poses a problem. Tsui et 
al proposed an ischemic index (non-perfused retina/gradable retina) on ultra-
widefield angiography, and reported that eyes that develop neovascularization have 
a mean ischemic index of 75% in contrast to eyes that did not with a mean ischemic 
index of only 6%.7 The authors also concluded that eyes with an ischemic index of 
45% have a greater likelihood of developing neovascularization.7 However, the 
images used were not corrected for three dimensions to two dimension projection 
errors leading to a magnification of the periphery compared to the center as well as a 
horizontal stretch.8,9 Efforts have been made to correct for these artifacts and Optos, 
Dunfermline, United Kingdom has incorporated a correction into the V2 Vantage Pro 
software which now produces a stereographically corrected image.10 Despite this 
improvement, we have found that images are still enlarged in the periphery by using 
3-D printed model eyes.11  
Furthermore, there is evidence that anti-VEGF therapy does modify the natural 
history of CRVO. Therefore, the guidance obtained from the CVOS study whereby it 
was acceptable to wait for the development of neovascularization before performing 
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panretinal photocoagulation cannot be translated into practice because intravitreal 
anti-VEGF treatment may mask or delay the development of neovascularization. The 
high-risk period of the first three months is now shifted with anti-VEGF therapy. The 
RAVE study reported the risk of neovascularization is not ameliorated but only 
delayed.12 It has also been reported that following regular intravitreal anti-VEGF 
treatment, the treatment free interval prior to the development of neovascular events 
was 6.2±7.3 months.13 This further highlights the necessity to risk stratify patients for 
either prophylactic panretinal photocoagulation or more intensive follow-up upon 
cessation or extension of the interval of anti-VEGF therapy. Using a 10DA of non-
perfusion as a guide with an incidence of new vessels of 35% will result in 65% of 
patients having unnecessary intensive follow-up clinic visits or prophylactic 
treatment. 
Therefore, to enhance our understanding of the development of neovascularization 
in eyes with CRVO and to risk-stratify our patients better when ultra-widefield 
angiography is used, we performed a retrospective analysis of corrected ultra-
widefield angiography images of eyes with CRVO to evaluate the area and 
distribution of retinal non-perfusion that is most predictive of neovascularization.  
 
Methods 
This retrospective consecutive case series and image analysis study was performed 
in the National Institute for Health Research Moorfields Biomedical Research Centre 
and the Institute of Ophthalmology, University College London, United Kingdom. 
Local institutional review board approval was obtained for analysis of anonymised 
data and the study was conducted in accordance with the tenets of the Declaration 
of Helsinki (Registration number 15006). 
Inclusion criteria and data collection 
A total of 1659 patients with a diagnosis of CRVO were identified from the medical 
retina service database. From this group, eyes that had been imaged with Optos 
ultra-widefield angiography using standard local protocols were identified. Images 
were excluded if they were not of sufficient clarity, defined as the ability to clearly 
discern perfused from nonperfused capillaries. The observation period was a 
minimum of 12 months from diagnosis or until the development of 
neovascularization. Eyes treated with intravitreal agents or prophylactic panretinal 
photocoagulation either previously or during the observation period were also 
excluded from the analysis. The effect of anti-vascular endothelial growth factor 
(VEGF) on the area of retinal non-perfusion is debatable with contradictory reports 
published and therefore patients with prior treatment were excluded.14,15 The 
definition of neovascular complications in our study were iris new vessels, new 
vessels at the angles, disc new vessels, retinal new vessels and vitreous 
hemorrhage. Treatment was permitted after the development of neovascular 
changes. Eyes that develop neovascularization must have had ultra-widefield 
angiography within two months of the date of documented neovascular complication 
to reduce the likelihood of underestimating the area of non-perfusion should an eye 
convert to an ischemic form following diagnosis. 
Image acquisition  
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The ultra-widefield angiography was performed with the Optos 200TX (Optos Plc, 
Dumfermline, Scotland) ultra-widefield system using a standard protocol after 
intravenous bolus infusion of 5 mL of 20% fluorescein sodium. The protocol 
consisted of acquiring images in transit phase (up to 45s), arteriovenous phases (1-
2min), and late frames at 3-4 minutes and 7-8 minutes. A single investigator (L.N.) 
identified the best macula centered fluorescein angiography (FA) image in the 
arteriovenous phase from the FA series of each eligible eye.  
Image processing 
A correction factor was applied for the flattening of the 3-dimensional image to a 2-
dimensional image using a non-commercial research tool under development by 
Optos at the time of the study but now available as part of the Optos V2 Vantage Pro 
software. The concentric rings template was applied to each image according to 
previously described methods.16 In brief, this validated method incorporates a 
macular ring with a radius of 2.5 disc diameters (DD) and five additional concentric 
rings (rings 1-5), each with a 2.5DD increment in radius.16 Each of the six rings (Ring 
M and 1-5) were divided into 12 segments (Figure 1). Each segment is graded as 
upgradeable, not-perfused or perfused if 50% or more of the segment is involved.16 
In addition to quantifying non-perfusion, the concentric rings method allows 
documentation of location of non-perfusion. The area of each cell in each concentric 
ring was modified based on the enlargement factor identified using 3-D printed 
model eyes.11 The enlargement factor for rings M, 1, 2, 3, 4, and 5 were 1.08, 1.20, 
1.34, 1.54, 1.81 and 1.97 respectively.11 Therefore, the modified area of each 
segment in each ring is now represented in Table 1. We did not use the eye-steering 
images in our cohort. We feel the montaged image using the three images (superior, 
central, inferior) introduces projection distortions that as yet has not been studied or 
validated as the location of the same area of the retina is distorted differently in 
different images given the different angular location.11 Therefore, we elected to only 
use the central image as the projection distortion in this has previously been studied 
and we have made the appropriate corrections.11 
Data collection and analysis 
Measurement of retinal nonperfusion from ultra-widefield angiography was 
performed using the concentric rings method. The location and area of retinal non-
perfusion (measured in disc areas, DA) were determined using the concentric rings 
method.16 The macular ring and ring 1 corresponds to the posterior pole while rings 2 
to 5 corresponds to the periphery. The images were graded by two retinal physicians 
and average measurements were used to increase reliability. Alternative methods to 
quantify retinal non-perfusion include the ischemic index but this method only 
quantifies retinal non-perfusion as a ratio and does not give us the pattern of 
ischemia.7 We elected to quantify non-perfusion as disc areas rather than in mm2 as 
historically we have been accustomed to disc areas as a measure of retinal non-
perfusion on fluorescein angiograms and therefore comparisons can be made 
simple.  
Statistical analysis 
Descriptive statistics were used to present the data. The agreement between the two 
graders was expressed as intraclass correlation coefficients. The association 
between patterns of retinal non-perfusion and the development of neovascularization 
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was studied using a 2X2 contingency table and applying the Fisher's Exact test. A 
Kaplan-Meier curve was used to report the time to neovascular events in our cohort. 
Differences between means were assessed with a Mann Whitney U Test. Risks were 
expressed as odds ratio and applying a two tailed Fisher’s Exact test to assess 
statistical significance. Statistical significance was set at 0.05. 
 
Results 
A total of 114 consecutive patients with central retinal vein occlusion and imaged 
with ultra-widefield angiography that attended Moorfields Eye Hospital, London, 
United Kingdom, between January 2014 and December 2014, were assessed. There 
were 42 treatment naïve non-diabetic eyes with central retinal vein occlusion from 41 
patients with gradable UWF-A and a minimum of 12 months follow-up was identified 
and the development of new vessels in that period was recorded.  
The mean (+SD) age at diagnosis of patients in this study was 61.2 ± 16.5 years. 
There were 24 (58.5%) males and 20 (47.6%) were right eyes. The median duration 
between diagnosis and UWF-A was 17 days. The Intraclass correlation coefficient 
(ICC) for grading areas non-perfusion among the two graders was 0.951. 
Area of non-perfusion 
The mean area of non-perfusion in the whole cohort was 78.4DA ± 104.4 DA (range, 
0-403.9 DA). Thirteen out of 42 eyes (30.95%) developed neovascular 
complications.  The mean area of non-perfusion in eyes complicated by 
neovascularization was 177.4 DA [95% CI: 102.2, 252.6]. As for eyes with no 
neovascularization, (29 eyes), the mean area of non-perfusion was 34.1DA [95% CI: 
14.2, 53.9]. This difference was statistically significant, p<0.001 
There were 9 (21.4%) eyes that had no areas of non-perfusion while 12 (28.6%) 
eyes had less than 10 disc areas of non-perfusion. The incidence of new vessels 
was 0% with less than 10 DA of non-perfusion. This increases with increasing area 
of retinal non-perfusion as described in Table 2.  In eyes with less than 30 disc areas 
of retinal non-perfusion, 5.3% developed new vessels as opposed to 52.2% of eyes 
with more than 30 disc areas of retinal non-perfusion developing neovascularization. 
This is further detailed in Table 3. 
Location  
When each ring was assessed specifically, the incidence of developing new vessels 
is more than 80% if three or more cells in a single ring for rings M, 1 or 2 in the 
concentric rings were graded as not perfused. This is also reflected in eyes with 
more than 10 disc areas of non-perfusion in rings M and 1 whereby the incidence is 
also more than 80%. The risk of neovascularization is further detailed in Table 4 
where posterior pole involvement relates to a high risk of developing new vessels. 
There were 13 (31.0%) eyes that had more than 10DA of non-perfusion isolated in 
the periphery with a completely perfused posterior pole. Of these eyes, 1 (7.7%) 
developed new vessels. 13 (31.0%) eyes had more than 10DA of non-perfusion in 
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the posterior pole and of these, 11 (84.6%) developed new vessels. This association 
was found to be statistically significant, p=0.0002 (Table 5). Among these 13 eyes 
with more than 10DA of non-perfusion in the posterior pole, 6 (46.2%) developed 
anterior segment neovascularization. 
In a sub-analysis of macular non-perfusion, among the 12 eyes with non-perfusion in 
Ring M, 9 (75%) developed new vessels. In contrast, among the 17 eyes with retinal 
non-perfusion not involving Ring M, no eyes developed new vessels. A Kaplan-Meier 
curve for time to development of neovascular complications for our cohort is 
presented in Figure 2. 
We present two cases in our cohort, figure 3, which demonstrates the differences in 
isolated peripheral non-perfusion and posterior pole non-perfusion and its 
association with the development of neovascularization. The eye in example 1 has a 
lesser area of retinal non-perfusion compared with example 2, however, the posterior 
pole is involved in example 1 with three segments in Ring 1 being non-perfused. This 
eye did develop retinal new vessels. The eye in example 2 on the other hand, 
despite having a larger area of non-perfusion albeit no segments in Rings M, 1 or 2 
that are not perfused, did not develop new vessels. 
 
Discussion 
This is the first study reporting the incidence of neovascularization in central retinal 
vein occlusion based on a corrected area of retinal non-perfusion in ultra-widefield 
angiography as well as the distribution of retinal ischemia. As we are now imaging a 
significantly wider area of the retina, the traditional concept of 10 disc areas of retinal 
non-perfusion as a definition of an ischemic central retinal vein occlusion in ultra-
widefield angiography can be improved. In our cohort, eyes with areas of retinal non-
perfusion between 10-30 disc areas, 85.7% did not experience neovascularization. 
Increasing the threshold to 30 disc areas of non-perfusion appears a better indicator 
with 5.3% developing new vessels if less than 30 disc areas were involved and 
52.2% if this was exceeded. 
Despite the quantity of non-perfusion, the distribution of retinal non-perfusion is a 
sensitive determinant of neovascularization. Involvement of the posterior pole 
appears to harbor a significant risk of developing new vessels with 84.6% of eyes 
with more than 10 disc areas in the posterior pole (rings M and 1) experiencing this 
complication with an odds ratio of 74.3. We have also found that involvement of the 
posterior pole is related to a larger total area of retinal non-perfusion as well. 
Interestingly, should the posterior pole remain perfused, despite large areas of non-
perfusion in the periphery (more than 10 disc areas), the risk of neovascular 
complications remains very low, neovascularization incidence of 7.7% and odds ratio 
of 0.12. This further reduces the significance of a global 10 disc areas of non-
perfusion as a definition for an ischemic retinal vein occlusion as these patients are 
unlikely to develop neovascular complications. This could be explained by the fact 
that the peripheral retina is thinner and inner retinal ischemia which could be 
compensated by the choroid has less of an impact as opposed to ischemia in the 
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posterior pole. In regards to the implication on panretinal photocoagulation, as 
posterior non-perfusion is frequently associated with a larger total area of non-
perfusion which is inclusive of the periphery, there is still place for peripheral 
panretinal photocoagulation. However, this also helps explain the finding that despite 
peripheral panretinal laser, persistent new vessels in diabetic retinopathy exist and 
20% of prophylactically treated eyes in the CVOS study still progressed to significant 
neovascular events.2 This implies that in these very ischemic eyes with resistant 
cases of neovascularization, panretinal laser involving the posterior pole may be 
required.  
The quantity of retinal non-perfusion in each ring from the concentric rings method is 
an alternative method to risk stratify the incidence of neovascularization. The area of 
each segment progressively increases with each subsequent ring towards the 
periphery as described in Table 1. The significance of three segments or more of 
retinal non-perfusion in a single ring appears to confer to an increased incidence of 
neovascularization which is can translate to a practical method to utilize in clinical 
practice.  
The importance of making adjustments to the peripheral distortion in ultra-widefield 
imaging is also essential in our understanding of the area of non-perfusion. Tsui et al 
identified a mean ischemic index of 75% among eyes that develop 
neovascularization.7 While, in our cohort, the corresponding ischemic index taking 
into account the correction factors described, the mean ischemic index was 52% for 
eyes that develop new vessels.  
The need for ultra-widefield imaging is then brought into question as a standard 
ETDRS seven field will be sufficient to image the posterior pole thus potentially 
identifying these patients that are high risk for developing neovascular complications.   
In figure 4, we have superimposed the concentric rings with a standard seven field 
coverage. Rings M and 1 are shaded and is included in the standard seven field 
imaging. Therefore, this implies that standard seven-field imaging is sufficient to 
predict neovascularization and 10DA within the posterior pole remains a very 
important threshold. Knowledge of the area and pattern of non-perfusion in ultra-
widefield imaging is required if this imaging modality is used. The ultra-widefield 
system still provides a whole image that is in-phase as opposed to seven different 
phases montaged into a single image. It has also been reported to identify 
significantly more new vessels and retinal pathology compared to standard seven 
field imaging.17 We need to add that the standard seven field also incorporates 
almost 8 segments in ring 2 and almost three segments in ring 3. The inclusion of 
parts of rings 2 and 3 in the standard seven field may result in a larger number of 
eyes classified as ischemic using standard seven fields but less than 10DA if just 
studying the posterior pole. This may explain why a lower percentage progress to 
anterior segment neovascular events, 35%, in the CVOS study compared to our 
cohort, 45% anterior segment neovascularization and 84.6% any neovascular 
events.  
The limitations of our study include the retrospective nature of the study and the 
exclusion of treated eyes that may introduce a recruitment bias towards a lower 
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tendency for neovascularization. However, our cohort had an incidence of 
neovascularization at 31%, and the standard deviation for the area on non-perfusion 
was high at 104DA indicating a good spread of patients with CRVO were included. 
Gonioscopy was only performed if deemed necessary by the examining clinician. 
Therefore, early angle new vessels may have been missed but we believe this is 
very unlikely. We also acknowledge the numbers included in the study are small. 
However, ultra-widefield angiography has only been used in routine practice in the 
last few years and so we believe that these findings are timely.  
In conclusion, posterior pole non-perfusion in CRVO is more prone to new vessel 
development compared to isolated peripheral non-perfusion. Posterior pole retinal 
non-perfusion is also associated with a larger area of retinal non-perfusion in total. 
Moreover, our understanding of anti-VEGF induced disease modification and the risk 
of neovascularization when some eyes are withdrawn from anti-VEGF therapy is 
only becoming more apparent. Therefore, we believe that the observations of this 
study will help identify patients at risk of developing delayed anterior 
neovascularisation on ultrawide imaging before commencing anti-VEGF therapy so 
that they can either be treated with panretinal photocoagulation or followed up 
closely for early identification of neovascularization.  
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Figure Captions 
Figure 1: The concentric rings template with 6 concentric rings, Ring M and Ring 1 
representing the posterior pole, Ring 2-5 representing the periphery.  
Figure 2: Kaplan-Meier time to neovascular event curve for eyes with central retinal 
vein occlusion that developed neovascular complications. 
Figure 3: Ultra-widefield fluorescein angiogram image of two eyes with central retinal 
vein occlusion with the concentric rings superimposed, example 1(left) and example 
2 (right). The segments of the rings are colored to demonstrate segments that are 
perfused (green), not perfused (Red) and upgradeable (purple). The development of 
new vessels and the total area of non-perfusion is also included. 
Figure 4: The concentric rings and standard seven field area superimposed on a 
corrected ultra-widefield image with the overlap between the standard seven field 
with rings M and 1 (pink) and Rings 2 and 3 (orange) marked. 
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Tables of Contents Statement 
 
This study reviewed the area and pattern of retinal non-perfusion as imaged using 
ultra-widefield angiography in eyes with central retinal vein occlusion and its 
association with neovascularization. The authors identified that posterior pole non-
perfusion is associated with a larger total area of retinal non-perfusion and a higher 
incidence and risk of neovascularization. 
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Table 1: The original and modified area per segment using the correct conversion 
factor for each ring in the concentric rings method. 
Ring 
Original area per 
segment, DA 
Enlargement 
Factor 
Modified area per 
segment, DA 
M 2.00 1.08 1.85 
1 6.25 1.20 5.21 
2 10.42 1.34 7.78 
3 14.58 1.54 9.47 
4 18.75 1.81 10.36 
5 22.92 1.97 11.63 
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Table 2: The incidence and risk of neovascularization in central retinal vein occlusion 
based on total area of non-perfusion in ultra-widefield angiography. 
 
 
aConfidence Interval 
Area of 
non-
perfusion, 
in disc 
areas 
Number 
of eyes, 
n 
No 
neovascularization, 
n (%) 
Neovascularization, 
n (%) 
Odds 
Ratio,  
(95% 
CIa) 
 
p-
value       
< 10 12 12 (100.0) 0 0 0.008 
10-30 7 6 (85.7) 1 (14.3) 
0.32 
(0.03, 
2.97) 
0.405 
30-75 10 8 (80.0) 2 (20.0) 
0.48 
(0.09, 
2.65) 
0.466 
75-150 5 1 (20.0) 4 (80.0) 
12.44 
(1.23, 
126.18) 
0.026 
>150 8 2 (25.0) 6 (75.0) 
11.57 
(1.91, 
70.24) 
0.006 
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Table 3: Incidence and risk of neovascularization in eyes with central retinal vein 
occlusion based on 10 and 30 disc areas of retinal non-perfusion in ultra-widefield 
angiography. 
aConfidence Interval 
 Area of non-perfusion, 
in disc areas 
Number of 
eyes, n 
Neovascularization, 
n (%) 
Odds 
Ratio, 
(95% CIa) 
p-
value 
< 10 12 0 0 0.008 
>10 30 13(43.3) ∞ 0.008 
<30 19 1 (5.3) 0.05 (0.01,0.45] 
0.002 
>30 23 12 (52.2) 
19.64 
(2.23, 
172.60] 
0.002 
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Table 4: The incidence and risk of neovascular complications based on number of 
eyes with more than 10 disc areas of non-perfusion and three or more cells of non-
perfusion in each concentric ring. 
 
Ring Eyes 
with 
>10 
DA in 
a 
single 
ring, 
n 
Neovascular 
complications, 
n (%) 
Odds 
ratio, 
(95% 
CIb) 
p-
value 
Eyes 
with ≥ 3 
cells 
graded 
as not 
perfused, 
n 
Neovascular 
complications, 
n (%) 
Odds 
ratio, 
(95% 
CIb) 
p-
value 
Ring 
M 
6 5 (83.3) 17.5 
(1.8, 
172.2) 
0.007 7 6 (85.7) 24.0 
(2.5, 
233.1) 
0.002 
Ring 
1 
13 11 (84.6) 74.3 
(9.3, 
595.3) 
<0.001 9 8 (88.9) 44.8 
(4.6, 
440.8) 
<0.001 
Ring 
2 
16 12 (75) 75 
(7.5, 
745.8) 
<0.001 13 11 (84.6) 74.3 
(9.3, 
595.3) 
<0.001 
Ring 
3 
17 12 (75) 12.6 
(2.8, 
56.1) 
<0.001 12 9 (75) 19.5 
(3.6, 
104.4) 
<0.001 
Ring 
4 
19 8 (42.1) 2.6 
(0.7, 
10.1) 
0.192 11 6 (54.5) 4.1 
(0.96, 
17.6) 
0.066 
Ring 
5a 
12 7 (58.3) 5.6 
(1.3, 
24.0) 
0.026 2 2 (100.0) ∞ 0.091 
aThe results in Ring 5 are variable due to the larger number of ungradable cells in 
that area. 
bConfidence Interval 
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Table 5: The incidence and risk of neovascularization based on the pattern of retinal 
non-perfusion, a completely perfused posterior pole (Ring M and 1) with more than 
10 disc areas of non-perfusion peripherally and more significant posterior pole retinal 
non-perfusion.  
 
Area of non-
perfusion  
Number 
of eyes  
Mean total 
area of 
non-
perfusion  
Number 
(Percentage) 
of neovascular 
complications  
Odds 
Ratio 
(95% CIa) 
p-
value 
Completely 
perfused 
Ring M and 1 
and >10DA 
of non-
perfusion in 
Rings 2-5  
13  43.2  
95% CI 
(18.7, 67.7)  
1 (7.7%)   0.12 
(0.01, 
1.03) 
0.036 
>10DA of 
non-
perfusion in  
Ring M and 1  
13  193.2 
95% CI 
(122.4, 
264.1) 
11 (84.6%)  74.25 
 (9.26, 
595.30) 
<0.001 
 
aConfidence Interval 
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